Patient characteristics at study entry
Characteristics . | Data . |
|---|---|
| No. patients | 27 |
| Age, y, median (range) | 48 (16-63) |
| Sex, no. (%) | |
| Male | 14 (52) |
| Female | 13 (48) |
| Breakpoint, no. (%) | |
| M-Bcr-Abl (b2a2, b3a2) | 7 (26) |
| m-Bcr-Abl (e1a2) | 20 (74) |
| Prior imatinib therapy, no. (%) | |
| In CR1 during first-line therapy | 9 (33) |
| Salvage therapy | 9 (33) |
| Type of transplantation, no. (%) | |
| Autologous | 3 (11) |
| Allogeneic | 24 (89) |
| Matched related | 14 (58) |
| Matched unrelated | 9 (38) |
| 1 antigen-mismatch unrelated | 1 (4) |
| Disease status at SCT, no. (%) | |
| CR1 | 21 (78) |
| First or second relapse | 3 (11) |
| Refractory | 2 (7) |
| PR | 1 (4) |
| Conditioning, no. (%) | |
| Nonmyeloablative | 7 (26) |
| Myeloablative | 20 (74) |
| TBI-based | 17 (85) |
| Non-TBI-based | 3 (15) |
| Time from SCT to MRD+, mo, median (range) | 3.6 (0.5-18.2) |
| Time from SCT to imatinib start, mo, median (range) | 4.4 (1.1-19.2) |
| GvHD, no. (%) | |
| Active GvHD | 11 (46) |
| Acute GvHD grades I-II | 2 |
| Chronic GvHD | 9 |
| Limited | 8 |
| Extensive | 1 |
| Immunosuppressive therapy, no. (%) | |
| Steroids | 2 |
| CSA | 4 |
| Steroids and CSA | 5 |
| WBCs × 109/L, median (range) | 5.8 (3.1-13.2) |
| ANC × 109/L, median (range) | 3.9 (1.3-7.1) |
| Platelets × 109/L, median (range) | 157 (41-370) |
Characteristics . | Data . |
|---|---|
| No. patients | 27 |
| Age, y, median (range) | 48 (16-63) |
| Sex, no. (%) | |
| Male | 14 (52) |
| Female | 13 (48) |
| Breakpoint, no. (%) | |
| M-Bcr-Abl (b2a2, b3a2) | 7 (26) |
| m-Bcr-Abl (e1a2) | 20 (74) |
| Prior imatinib therapy, no. (%) | |
| In CR1 during first-line therapy | 9 (33) |
| Salvage therapy | 9 (33) |
| Type of transplantation, no. (%) | |
| Autologous | 3 (11) |
| Allogeneic | 24 (89) |
| Matched related | 14 (58) |
| Matched unrelated | 9 (38) |
| 1 antigen-mismatch unrelated | 1 (4) |
| Disease status at SCT, no. (%) | |
| CR1 | 21 (78) |
| First or second relapse | 3 (11) |
| Refractory | 2 (7) |
| PR | 1 (4) |
| Conditioning, no. (%) | |
| Nonmyeloablative | 7 (26) |
| Myeloablative | 20 (74) |
| TBI-based | 17 (85) |
| Non-TBI-based | 3 (15) |
| Time from SCT to MRD+, mo, median (range) | 3.6 (0.5-18.2) |
| Time from SCT to imatinib start, mo, median (range) | 4.4 (1.1-19.2) |
| GvHD, no. (%) | |
| Active GvHD | 11 (46) |
| Acute GvHD grades I-II | 2 |
| Chronic GvHD | 9 |
| Limited | 8 |
| Extensive | 1 |
| Immunosuppressive therapy, no. (%) | |
| Steroids | 2 |
| CSA | 4 |
| Steroids and CSA | 5 |
| WBCs × 109/L, median (range) | 5.8 (3.1-13.2) |
| ANC × 109/L, median (range) | 3.9 (1.3-7.1) |
| Platelets × 109/L, median (range) | 157 (41-370) |
M indicates major; m, minor; CSA, cyclosporin A.